According to the review article "Transgenic mouse models are a perfect tool for studying the processes involved in pulmonary vascular function and disease, and can be used effectively to test interventions designed against particular molecular pathways and processes involved in disease." Unfortunately, any attempt to extrapolate results between complex systems with different evolutionary trajectories (mice and humans are examples of complex systems, separated by 70 million years) will be limited to conserved processes whose trait or response being studied occurs at the same level of organization or in the same module. [5] Pulmonary vascular function has both intrinsic and extrinsic multifactorial genetic components, which are not amenable to such reductionist study. Genes work in networks and in the context of complex systems, small changes at the gene level can have major consequences for the individual. Thus, it is irrelevant to focus on observed similarities in genetic makeup (including transgenes) between mice and humans, since the details of the differences are in the interactions between conserved genes, not in the genes themselves. [6] We conclude that the use of animals as human models for drug and disease research ignores the very principles upon which modern personalized medicine is based. Therefore, human-based research should become the primary means for obtaining data about human diseases and response to drugs. [7] Author's Reply
We entirely agree that humans are, theoretically, the best system in which to study human disease. To some extent, the problem with mouse modeling is even worse than Drs Menache and Keogh claim: Not only do mice have different responses to pulmonary vascular stress than do humans, but different strains of mice have rather different responses compared to each other, on both a physiologic and molecular level. [1] Moreover, I doubt even the most optimistic mouse modeler believes that any of the dozens of substances that reverse monocrotaline-related pulmonary arterial hypertension (PAH) are likely to be directly relevant to human disease. [2] This is not, however, a reason to abandon mouse modeling. The problem is that there are a great many questions that simply cannot be effectively studied in humans. For instance, the largest expression array study performed directly on lungs from humans with pulmonary hypertension found that of 14,000 genes with detectable levels of expression; 13,889 had significant changes. [3] The signal of etiologic change was overwhelmed with the noise of damage associated with end-stage disease. It is not possible to study initiating events in idiopathic pulmonary hypertension in humans; even with the best registries of not-yet-affected mutation carriers, conversion to disease is so slow that recruitment goals could not practically be met. There are also a great many experiments in gene-gene interaction, especially where these meet
